The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Canonical pathway of nuclear factor κB activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis
Open accessAbstract
Nuclear factor κB (NF-κB) activation has been observed in human atherosclerotic plaques and is enhanced in unstable coronary plaques, but whether such activation has a protective or pathophysiological role remains to be determined. We addressed this question by developing a short-term culture system of cells isolated from human atherosclerotic tissue, allowing efficient gene transfer to directly investigate signaling pathways in human atherosclerosis. We found that NF-κB is activated in these cells and that this activity involves p65, p50, and c-Rel but not p52 or RelB. This NF-κB activation can be blocked by overexpression of IκBα or dominant-negative IκB kinase (IKK)-2 but not dominant-negative IKK-1 or NF-κB-inducing kinase, resulting in selective inhibition of inflammatory cytokines (tumor necrosis factor α, IL-6, and IL-8), tissue factor, and matrix metalloproteinases without affecting the antiinflammatory cytokine IL-10 or tissue inhibitor of matrix metalloproteinases. Our results demonstrate that the canonical pathway of NF-κB activation that involves p65, p50, c-Rel, and IKK-2 is activated in human atherosclerosis and results in selective up-regulation of major proinflammatory and prothrombotic mediators of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,742
Phosphorylation meets ubiquitination: the control of NF-κB activity
Karin, M., & Ben-Neriah, Y. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.621 · Cited by 4,766
Current Concepts of the Pathogenesis of the Acute Coronary Syndromes
Libby, P. (2001) · Circulation · doi:10.1161/01.cir.104.3.365 · Cited by 1,558
The IKK NF-κB system: a treasure trove for drug development
Karin, M., Yamamoto, Y., & Wang, Q. M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1279 · Cited by 1,364
BRENNAN, F. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90430-3 · Cited by 1,129
Reduction of atherosclerosis in mice by inhibition of CD40 signalling
Mach, F., Schönbeck, U., Sukhova, G. K., Atkinson, E., & Libby, P. (1998) · Nature · doi:10.1038/28204 · Cited by 910
Protective Role of Interleukin-10 in Atherosclerosis
Mallat, Z., Besnard, S., Duriez, M., Deleuze, V., Emmanuel, F., Bureau, M. F., Soubrier, F., Esposito, B., Duez, H., Fievet, C., et al. (1999) · Circulation Research · doi:10.1161/01.res.85.8.e17 · Cited by 831
Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion.
Brand, K., Page, S., Rogler, G., Bartsch, A., Brandl, R., Knuechel, R., Page, M., Kaltschmidt, C., Baeuerle, P. A., & Neumeier, D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118598 · Cited by 798
Possible new role for NF-κB in the resolution of inflammation
Lawrence, T., Gilroy, D. W., Colville-Nash, P. R., & Willoughby, D. A. (2001) · Nature Medicine · doi:10.1038/nm1201-1291 · Cited by 749
Sato, H., & Seiki, M. (1993) · PubMed · Cited by 695
Cited by
NF-κB signaling in inflammation
Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.23 · Cited by 8,791
The Nuclear Factor NF- B Pathway in Inflammation
Lawrence, T. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001651 · Cited by 4,898
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Tedgui, A., & Mallat, Z. (2006) · Physiological Reviews · doi:10.1152/physrev.00024.2005 · Cited by 1,701
INFLAMMATION AND ATHEROSCLEROSIS
Hansson, G. K., Robertson, A.-K. L., & Söderberg-Nauclér, C. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100100 · Cited by 1,046
Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches
Park, M., & Hong, J. (2016) · Cells · doi:10.3390/cells5020015 · Cited by 627
NF‐κB signaling in inflammation and cancer
Zhang, T., Ma, C., Zhang, Z., Zhang, H., & Hu, H. (2021) · MedComm · doi:10.1002/mco2.104 · Cited by 574
Betaine in Inflammation: Mechanistic Aspects and Applications
Zhao, G., He, F., Wu, C., Li, P., Li, N., Deng, J., Zhu, G., Ren, W., & Peng, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01070 · Cited by 476
Deletion of LOX-1 Reduces Atherogenesis in LDLR Knockout Mice Fed High Cholesterol Diet
Mehta, J. L., Sanada, N., Hu, C. P., Chen, J., Dandapat, A., Sugawara, F., Satoh, H., Inoue, K., Kawase, Y., Jishage, K.-I., et al. (2007) · Circulation Research · doi:10.1161/circresaha.107.149724 · Cited by 443
Schultz-Hector, S., & Trott, K.-R. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.08.071 · Cited by 399
NF‐κB and innate immunity in ischemic stroke
Harari, O. A., & Liao, J. K. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05735.x · Cited by 311
Hasselbalch, H. C. (2012) · Blood · doi:10.1182/blood-2011-11-394775 · Cited by 300
Mitochondria and Reactive Oxygen Species: Physiology and Pathophysiology
Bolisetty, S., & Jaimes, E. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14036306 · Cited by 273
Pamukcu, B., Lip, G. Y. H., & Shantsila, E. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.03.025 · Cited by 218
“hway is involved in every stage [28–48]”
BackgroundInflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
Li, B., Li, W., Li, X., & Zhou, H. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161230142931 · Cited by 130
“Blockade of IkB kinase β/2 abolishes cytokine production in human atherosclerosis [116].”
BackgroundNagenborg, J., Goossens, P., Biessen, E. A. L., & Donners, M. M. P. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.005 · Cited by 50
Kremers, B. M. M., Posma, J. N., Heitmeier, S., Glunz, J., ten Cate, H., Pallares Robles, A., Daemen, J. H. C., ten Cate-Hoek, A. J., Mees, B. M. E., & Spronk, H. M. H. (2022) · Scientific Reports · doi:10.1038/s41598-022-23260-3 · Cited by 17
Noh, J.-W., Lee, H.-Y., & Lee, B.-C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315329 · Cited by 17
“In silico experiments revealed hub pathways of overlapped genes between insulin resistance and MGF, and showed that the significant pathways were NF-κB, MAPK, and PI3K-AKT signaling [17].”
Background
Metadata
- Authors
- Monaco, C., Andreakos, E., Kiriakidis, S., Mauri, C., Bicknell, C., Foxwell, B., Cheshire, N., Paleolog, E., & Feldmann, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-04-02
- Volume
- 101
- Issue
- 15
- Pages
- 5634-5639
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2032766057
- Cited by
- 348
- References
- 36
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.